{
    "clinical_study": {
        "@rank": "104051", 
        "arm_group": [
            {
                "arm_group_label": "ISIS-FXIRx Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Group B: ISIS-FXIRx Dose #2"
            }, 
            {
                "arm_group_label": "ISIS-FXIRx Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Group C: ISIS-FXIRx Dose #3"
            }, 
            {
                "arm_group_label": "Enoxaparin", 
                "arm_group_type": "Active Comparator", 
                "description": "Enoxaparin (40mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is:\n\n        -  To assess the safety and efficacy profile of ISIS-FXIRx, including incidence of\n           bleeding and VTE, in patients undergoing total knee arthroplasty.\n\n        -  To compare the efficacy and safety profile of ISIS-FXIRx in patients who achieve less\n           than or equal to 0.2 U/mL FXI activity levels to that of enoxaparin."
        }, 
        "brief_title": "Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Thromboembolism", 
        "condition_browse": {
            "mesh_term": [
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Give written informed consent\n\n          -  Females must be non-pregnant and non-lactating, and either surgically sterile or\n             post-menopausal. Males must be surgically sterile, abstinent, or if engaged in sexual\n             relations of child-bearing potential, must use contraception\n\n          -  Undergoing elective, primary unilateral total knee arthroplasty\n\n        Exclusion Criteria:\n\n          -  Body weight <50 kg\n\n          -  Patients at increased risk of bleeding. History of intracranial or intraocular\n             bleeding. History of gastrointestinal and/or endoscopically verified ulcer disease\n             within the past year.\n\n          -  History of excessive intra- or direct post operative bleeding or a traumatic spinal\n             or epidural anesthesia\n\n          -  Brain, spinal, or ophthalmologic surgery within the past 3 months\n\n          -  History of clinically significant liver disease in the past year\n\n          -  Screening laboratory results as follows, or any other clinically significant\n             abnormalities in screening laboratory values\n\n               -  aPTT or PT or INR >ULN\n\n               -  Factor IX activity <LLN\n\n               -  Factor VIII activity, vWF antigen or Ristocetin cofactor activity <0.5 U/mL\n\n               -  FXI activity <0.3 U/mL\n\n               -  Urine protein or blood persistently positive by dipstick. In the event of\n                  positive test results, eligibility may be confirmed with urine microscopy or 24\n                  hour urine protein measurement as applicable\n\n               -  ALT or AST >1.5 x ULN\n\n               -  Total bilirubin >ULN\n\n               -  Platelet count <150,000 (or history of thrombocytopenia)\n\n          -  Hypersensitivity to enoxaparin\n\n          -  Anticipated concomitant use of anticoagulants/antiplatelet agents or the NSAID\n             nimesulide that may affect study outcome or any other drug influencing coagulation\n             (except low dose aspirin and short acting NSAIDs with a half-life <20 hours) at least\n             7 days before surgery or during treatment with ISIS Rx.\n\n          -  Anticipated use of indwelling intrathecal or epidural catheters\n\n          -  Anemia at Screening\n\n          -  Have any other conditions which could interfere with the patient participating in or\n             completing the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713361", 
            "org_study_id": "ISIS 416858-CS3"
        }, 
        "intervention": [
            {
                "arm_group_label": "ISIS-FXIRx Dose 2", 
                "description": "Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.", 
                "intervention_name": "ISIS-FXIRx Dose #2", 
                "intervention_type": "Drug", 
                "other_name": "ISIS-FXIRx"
            }, 
            {
                "arm_group_label": "ISIS-FXIRx Dose 3", 
                "description": "Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.", 
                "intervention_name": "ISIS-FXIRx Dose #3", 
                "intervention_type": "Drug", 
                "other_name": "ISIS-FXIRx"
            }, 
            {
                "arm_group_label": "Enoxaparin", 
                "description": "Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). [Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.]", 
                "intervention_name": "Enoxaparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lovenox", 
                    "Clexane"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Enoxaparin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "total knee arthroplasty", 
            "Prophylaxis"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Plovdiv", 
                        "country": "Bulgaria", 
                        "zip": "4002"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rousse", 
                        "country": "Bulgaria", 
                        "zip": "7002"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1527"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ajax", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "LIS 2J4"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oshawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "LIG 2B9"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adazi", 
                        "country": "Latvia", 
                        "zip": "LV 2164"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia", 
                        "zip": "LV 1004"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valmiera", 
                        "country": "Latvia", 
                        "zip": "LV4201"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation", 
                        "zip": "454026"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orenburg", 
                        "country": "Russian Federation", 
                        "zip": "460000"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194354"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194291"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "193312"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samara", 
                        "country": "Russian Federation", 
                        "zip": "443095"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yaroslavl", 
                        "country": "Russian Federation", 
                        "zip": "150047"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cherkassy", 
                        "country": "Ukraine", 
                        "zip": "18009"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ivano-Frankivsk", 
                        "country": "Ukraine", 
                        "zip": "76000"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine", 
                        "zip": "61024"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyiv", 
                        "country": "Ukraine", 
                        "zip": "01107"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odessa", 
                        "country": "Ukraine", 
                        "zip": "65025"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevastopol", 
                        "country": "Ukraine", 
                        "zip": "99018"
                    }, 
                    "name": "Isis Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Canada", 
                "Latvia", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty", 
        "overall_official": {
            "affiliation": "VP, Clinical Development, Isis Pharmaceuticals", 
            "last_name": "Sanjay Bhanot, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Ukraine: Ministry of Health", 
                "Latvia: State Agency of Medicines", 
                "Bulgaria: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Composite of asymptomatic DVT (via bilateral venography), and symptomatic VTE, fatal PE, and unexplained death.", 
            "measure": "Primary efficacy outcome", 
            "safety_issue": "Yes", 
            "time_frame": "up to 12 days post-surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713361"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "All DVTs and PEs up to 4 weeks after bilateral venography", 
            "measure": "Secondary efficacy outcome", 
            "safety_issue": "Yes", 
            "time_frame": "1st dose to up to Day 76"
        }, 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}